Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez
- PMID: 30352886
- DOI: 10.1136/annrheumdis-2018-214477
Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez
Keywords: CLINICAL TRIAL; disease activity; pulmonary fibrosis; systemic sclerosis; tocilizumab.
Conflict of interest statement
Competing interests: DK is a consultant for Genentech/Roche. CJFL and AJ are employed by Genentech.
Comment on
-
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24. Ann Rheum Dis. 2018. PMID: 29066464 Free PMC article. Clinical Trial.
-
Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series.Ann Rheum Dis. 2019 Nov;78(11):e123. doi: 10.1136/annrheumdis-2018-214449. Epub 2018 Oct 23. Ann Rheum Dis. 2019. PMID: 30352892 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical